Company Filing History:
Years Active: 2024-2025
Title: Kalyana Chakravarthi Dulla: Innovator in RNA Editing and Antisense Oligonucleotides
Introduction
Kalyana Chakravarthi Dulla is a prominent inventor based in Leiden, Netherlands. He has made significant contributions to the fields of medicine and biotechnology, particularly in the development of innovative treatments for genetic disorders. With a total of 2 patents, Dulla is recognized for his groundbreaking work in RNA editing and antisense oligonucleotides.
Latest Patents
Dulla's latest patents include two notable inventions. The first is focused on RNA-editing oligonucleotides for the treatment of Usher syndrome. This invention relates to RNA editing oligonucleotides that can specifically edit a target nucleotide (adenosine) in a target RNA molecule within eukaryotic cells. The oligonucleotide is designed for use in treating Usher syndrome, particularly for the deamination of target adenosines that are part of a premature stop codon present in the USH2A pre-mRNA or USH2A mRNA. The second patent involves antisense oligonucleotides for the treatment of Stargardt disease. This invention pertains to novel antisense oligonucleotides (AONs) that can be utilized in the treatment, prevention, and/or delay of Stargardt disease and ABCA4-associated eye disease. Specifically, it focuses on AONs that inhibit or block exon 39 skipping in the human ABCA4 pre-mRNA.
Career Highlights
Dulla is currently associated with Proqr Therapeutics II B.V., where he continues to advance his research and innovations. His work is pivotal in developing therapies that address significant medical challenges.
Collaborations
Some of Dulla's notable coworkers include Aliye Seda Yilmaz-Elis and Peter Adamson. Their collaborative efforts contribute to the success of their projects and the advancement of their research.
Conclusion
Kalyana Chakravarthi Dulla is a distinguished inventor whose work in RNA editing and antisense oligonucleotides is paving the way for new treatments for genetic disorders. His contributions are vital to the ongoing advancements in biotechnology and medicine.